Ferruginol

Ferruginol

SCHEMBL155580

CC(C)c1cc2c(cc1O)[C@@]1(C)CCCC(C)(C)[C@@H]1CC2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KARS1 Q15046 2/20 0.73
▸ CYP19A1 P11511 1/20 0.59
▸ USP2 O75604 3/20 0.56
▸ CYP3A4 P08684 3/20 0.56
▸ MAPT P10636 3/20 0.56
▸ KDM4E B2RXH2 2/20 0.56
▸ MEN1 O00255 2/20 0.56
▸ TP53 P04637 2/20 0.56
▸ MAPK1 P28482 2/20 0.56
▸ KMT2A Q03164 2/20 0.56
▸ HSP90AA1 P07900 1/20 0.56
▸ FDPS P14324 7/20 0.53
▸ NR1I2 O75469 1/20 0.53
▸ OPRK1 P41145 1/20 0.53
▸ BCL9 O00512 3/20 0.52
▸ CTNNB1 P35222 3/20 0.52
▸ ALDH1A1 P00352 2/20 0.52
▸ HPGD P15428 2/20 0.52
▸ PTGES O14684 1/20 0.52
▸ CYP2C9 P11712 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ferruginol SCHEMBL13423521 1.00 KARS1 (0.73) KARS1CYP19A1USP2CYP3A4MAPT
Ferruginol SCHEMBL5315022 1.00 KARS1 (0.73) KARS1CYP19A1USP2CYP3A4MAPT
Sempervirol SCHEMBL10524413 0.95 KARS1 (0.66) KARS1CYP19A1USP2CYP3A4MAPT
Sempervirol SCHEMBL10524412 0.95 KARS1 (0.66) KARS1CYP19A1USP2CYP3A4MAPT
Sempervirol SCHEMBL29495146 0.95 KARS1 (0.66) KARS1CYP19A1USP2CYP3A4MAPT
SCHEMBL18290298 0.88 KARS1 (0.58) KARS1CYP19A1USP2CYP3A4MAPT
18-Hydroxyferruginol SCHEMBL32666150 0.85 KARS1 (0.67) KARS1USP2CYP3A4MAPTMEN1
18-Hydroxyferruginol SCHEMBL18290210 0.85 KARS1 (0.67) KARS1USP2CYP3A4MAPTMEN1
SCHEMBL21444399 0.85 KARS1 (0.57) KARS1CYP19A1USP2CYP3A4MAPT
Lambertic Acid SCHEMBL31674429 0.84 NR1I2 (0.74) KARS1CYP3A4NR1I2OPRK1BCL9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2006 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4714440-A2 A HEALING HERBAL-MINERAL COMPOSITION WITH ENHANCED EFFECTS Kurek, Janusz (PL) 2026-03-25 — — EP claimed
US-12568982-B2 Systems for retaining potency in an infused beverage VERTOSA INC. (US) 2026-03-10 — — US claimed
WO-2025083496-A1 COMPOSITIONS FOR SEBUM CONTROL Dyson Operations PTE. LTD. (SG) 2025-04-24 — — WO claimed
US-20250031741-A1 EMULSIONS AND DERIVATIVES FOR INFUSING HYDROPHOBIC ACTIVE AGENTS INTO AN EDIBLE PRODUCT VERTOSA INC. 2025-01-30 — — US claimed
WO-2025003164-A1 PROCESS FOR TREATING KERATIN FIBRES USING A COMPOSITION COMPRISING AT LEAST ONE PARTICULAR FATTY ACID, AT LEAST ONE OXYGENATED TERPENE COMPOUND AND AT LEAST ONE MODIFIED POLYSACCHARIDE L'OREAL (FR) 2025-01-02 — — WO claimed
WO-2025003165-A1 PROCESS FOR TREATING KERATIN FIBRES USING A COMPOSITION COMPRISING AT LEAST ONE PARTICULAR FATTY ACID, AT LEAST ONE OXYGENATED TERPENE COMPOUND AND AT LEAST ONE OLIGO/POLY-ESTER L'OREAL (FR) 2025-01-02 — — WO claimed
US-20240315965-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2024-09-26 — — US claimed
WO-2024126752-A1 PROCESS FOR TREATING KERATIN FIBRES USING A COMPOSITION COMPRISING A PARTICULAR FATTY ACID AND AN OXYGENATED TERPENE COMPOUND L'OREAL (FR) 2024-06-20 — — WO claimed
US-20230248041-A1 EMULSIONS AND DERIVATIVES FOR INFUSING HYDROPHOBIC ACTIVE AGENTS INTO AN EDIBLE PRODUCT VERTOSA INC. 2023-08-10 — — US claimed
WO-2022182527-A1 COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS Natural Extraction Systems, LLC (US) 2022-09-01 — — WO claimed
WO-2008061754-A1 DIETARY OR PHARMACEUTICAL COMPOSITIONS CONTAINING TRICYCLIC DITERPENES AND DERIVATIVES THEREOF FOR THE TREATMENT OF DEPRESSION DSM IP ASSETS B.V. (NL) 2008-05-29 — — WO claimed
WO-2008061720-A2 USE OF TRICYCLIC DITERPENES AND THEIR DERIVATIVES FOR THE TREATMENT, CO-TREATMENT OR PREVENTION OF INFLAMMATORY DISORDERS AND/OR JOINT DISORDERS DSM IP ASSETS B.V. (NL) 2008-05-29 — — WO claimed
EP-1925302-A1 Dietary or pharmaceutical compositions containing tricyclic diterpenes and derivatives thereof for the treatment of depression DSMIP Assets B.V. (NL) 2008-05-28 — — EP claimed
EP-1925301-A1 Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders DSMIP Assets B.V. (NL) 2008-05-28 — — EP claimed
WO-2005073154-A1 A METHOD OF EXTRACTING TOTAROL AND/OR A PRODUCT CONTAINING TOTAROL MENDE DOUGLAS ANTHONY (NZ) 2005-08-11 — — WO claimed
US-6331551-B1 COSMETIC FORMULATION FOR TREATING SKIN DISORDER CAUSED BY MICROBIAL INFECTION, COMPRISING SCLAREOL-LIKE OR SCLAREOLIDE-LIKE COMPOUND IN COSMETICALLY ACCEPTABLE CARRIER ISP INVESTMENTS LLC 2001-12-18 — — US claimed
EP-0686027-B1 Verwendung eines phenolischen Diterpens zur Herstellung einer Zusammensetzung zur therapeutischen Verwendung auf der Haut NORAC TECHNOLOGIES INC (CA) 1998-07-29 — — EP claimed
EP-0686027-A1 Verwendung eines phenolischen Diterpens zur Herstellung einer Zusammensetzung zur therapeutischen Verwendung auf der Haut NORAC TECHNOLOGIES INC. (CA) 1995-12-13 — — EP claimed
US-5358752-A Contains carnosic acid and/or derivatives as antioxidant NORAC TECHNOLOGIES INC. (CA) 1994-10-25 — — US claimed
WO-1994018941-A1 SKIN CARE COMPOSITION NORAC TECHNOLOGIES INC. (CA) 1994-09-01 — — WO claimed
Send feedback